What is a stock summary page? Click here for an overview.
Business Description
Marker Therapeutics Inc
NAICS : 325414
SIC : 2834
ISIN : US8760334081
Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.68 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 34.6 | |||||
| 3-Year EPS without NRI Growth Rate | 36.1 | |||||
| 3-Year FCF Growth Rate | 33.1 | |||||
| 3-Year Book Growth Rate | -33.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.89 | |||||
| 9-Day RSI | 37.21 | |||||
| 14-Day RSI | 37.91 | |||||
| 3-1 Month Momentum % | -50.8 | |||||
| 6-1 Month Momentum % | -43.54 | |||||
| 12-1 Month Momentum % | -66.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.15 | |||||
| Quick Ratio | 3.15 | |||||
| Cash Ratio | 2.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.6 | |||||
| Shareholder Yield % | -0.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -81.21 | |||||
| ROA % | -66.15 | |||||
| ROIC % | -1257.09 | |||||
| 3-Year ROIIC % | -61.56 | |||||
| ROCE % | -85.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.36 | |||||
| Price-to-Tangible-Book | 1.36 | |||||
| EV-to-EBIT | 0.49 | |||||
| EV-to-EBITDA | 0.49 | |||||
| EV-to-Forward-Revenue | 0.56 | |||||
| EV-to-FCF | 0.58 | |||||
| Price-to-Net-Current-Asset-Value | 1.37 | |||||
| Price-to-Net-Cash | 1.84 | |||||
| Earnings Yield (Greenblatt) % | 204.08 | |||||
| FCF Yield % | -70.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRKR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Marker Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.1 | ||
| Beta | 1.24 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.62 | ||
| Volatility % | 86.55 | ||
| 14-Day RSI | 37.91 | ||
| 14-Day ATR ($) | 0.160269 | ||
| 20-Day SMA ($) | 1.33675 | ||
| 12-1 Month Momentum % | -66.74 | ||
| 52-Week Range ($) | 1.1 - 5.99 | ||
| Shares Outstanding (Mil) | 10.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Marker Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Marker Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Marker Therapeutics Inc Frequently Asked Questions
What is Marker Therapeutics Inc(MRKR)'s stock price today?
The current price of MRKR is $1.14. The 52 week high of MRKR is $5.99 and 52 week low is $1.10.
When is next earnings date of Marker Therapeutics Inc(MRKR)?
The next earnings date of Marker Therapeutics Inc(MRKR) is 2025-05-15 Est..
Does Marker Therapeutics Inc(MRKR) pay dividends? If so, how much?
Marker Therapeutics Inc(MRKR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers